Navigation Links
Imaging Diagnostic Systems Generates Cash From Building Sale
Date:9/19/2007

$4.4 Million Available to Advance Premarket Approval Study and Current

Operations

FORT LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced completion of a financing arrangement intended to reduce its dependency on equity financing.

The Company has sold its headquarters building for $4.4 million in cash pursuant to a sale/leaseback agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO)

Tim Hansen, IMDS Chief Executive Officer, commented, "We are very pleased to have completed this arrangement. IMDS is at a critical point in its history; the market has never been more ready for a product like our CT Laser Mammography system (CTLM(R)). We have grown to eight sites participating in our U.S. clinical trials, and we may add more to accelerate data collection. We have tapped a cash source at the right time to support the PMA process without diluting our investors with continued drawing on our equity funding agreement. All of this is good news for our shareholders, who have patiently supported the Company through the lengthy product development stages. We believe this sale/leaseback move will help keep us financially and strategically poised to advance the PMA process and bring an exciting and revolutionary CTLM breast cancer imaging system to women worldwide."

Details of the sale/leaseback agreement are available in an 8K filing with the SEC.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CTLM is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:

Rick Lutz

(404) 261-1196

lcgroup@mindspring.com

Media Contact:

Elizabeth Williams

(954) 581-9800

williams@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Optimized Imaging of Protein Gels Stained with Coomassie Brilliant Blue Dye
2. Detect Released Oligosaccharides Using the Eagle Eye II Still Video Imaging System
3. Imaging Chemiluminescent Western Blots
4. Eagle Eye Optical Filter Optimized for Imaging Silver-Stained Gels
5. Imaging and Analysis of DIGE Product Information Sheet, Rev B
6. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
7. Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System
8. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
9. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
10. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
11. Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):